By InvitationPhase 3

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

United States174 participantsStarted 2023-08-11

Plain-language summary

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) in participants with cystic fibrosis (CF).

Who can participate

Age range1 Year

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓Meets at least 1 of the following criteria:

What they're measuring

Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)

Timeframe: From Baseline up to Week 100

Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)

Timeframe: From Baseline up to Week 196

Trial details

NCT IDNCT05844449

SponsorVertex Pharmaceuticals Incorporated

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2029-07-30

View on ClinicalTrials.gov More Cystic Fibrosis trials